SCHEMBL1474716

SCHEMBL1474716

Cc1ccc(OCc2cccc(-c3ccc4nc(-c5ccc(C)cc5)cn4c3)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 10/20 0.59
SLC2A1 P11166 1/20 0.59
CYP2C9 P11712 1/20 0.57
NR4A2 P43354 1/20 0.57
KCNH2 Q12809 1/20 0.57
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
KDM4E B2RXH2 2/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
MITF O75030 1/20 0.51
KDM5A P29375 1/20 0.51
KDM5C P41229 1/20 0.51
PAX8 Q06710 1/20 0.51
FFAR1 O14842 3/20 0.50
ALDH1A2 O94788 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
PKM P14618 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472663 0.95 NR4A2 (0.66) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1472923 0.93 ALDH1A3 (0.58) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1474701 0.92 FFAR1 (0.51) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1472990 0.91 MAOB (0.55) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1474910 0.88 ALDH1A1 (0.60) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1474690 0.85 RAB9A (0.54) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1472658 0.83 NR4A2 (0.80) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1472984 0.79 NR4A2 (0.73) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL1472245 0.79 NR4A2 (0.73) ALDH1A3SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL19322158 0.79 ALDH1A3 (0.64) ALDH1A3SLC2A1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US claimed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP claimed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US claimed
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US disclosed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 ALDH1A3 1043/4885SLC2A1 3269/4885CYP2C9 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.